Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation

Rheumatoid Arthritis Clinical Trial

— RHUMACOVID  

Official title:

Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04393233
• Other study ID #: RHUMACOVID ( 29BRC20.0110)
• Status: Recruiting
• Start date: April 23, 2020
• Est. completion date: May 23, 2020

Study information

• Verified date: April 2020
• Source: University Hospital, Brest
• Contact: Dewi GUELLEC
• Phone: +33298347264
• Email: dewi.guelle[@]chu-brest.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Most patients with Juvenile Rheumatoid Arthritis benefit from long-term immunmodulatory therapy (DMARD - disease modifying anti-rheumatic drug), more or less combined with regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.The present study will characterize this issue by defining the proportion of patients whose usual treatment of Rheumatoid Arthritis has been modified in relation to the actual sanitary crisis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: May 23, 2020
• Est. primary completion date: May 23, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Rheumatoid arthritis satisfying ACR/EULAR criteria

• Ongoing DMARD therapy

Exclusion Criteria:

• Inhability to consent

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• COVID
• Rheumatoid Arthritis

Locations

Country	Name	City	State
France	CHRU de Brest	Brest

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduction or discontinuation of the DMARD therapy in relation to the Covid-19 sanitary crisis	Reduction or discontinuation of treatment with sDMARD, bDMARD or tsDMARD	1 Day